Journal of the Neurological Sciences

Unaltered T cell responses to common antigens in individuals with Parkinson's disease.  444. 2023

Determinants of metabolic syndrome and its prognostic implications among stroke patients in Africa: Findings from the Stroke Investigative Research and Educational Network (SIREN) study.  441. 2022

Efficacy and safety of foslevodopa/foscarbidopa versus oral carbidopa/levodopa in advanced Parkinson's disease patients: Design of a phase 3, randomized, double-blind, double-dummy, active controlled 12-week trial.  429:119569. 2021

Sustained improvements in motor and non-motor symptoms in advanced Parkinson's disease patients treated with carbidopa levodopa enteral suspension in a ‘real-world’ study.  429:119562. 2021

Influence of age on links between major modifiable risk factors and stroke occurrence in West Africa.  428. 2021

It's tricky: Rating alleviating maneuvers in cervical dystonia.  419. 2020

Vascular-brain Injury Progression after Stroke (VIPS) study: concept for understanding racial and geographic determinants of cognitive decline after stroke.  412. 2020

Genetic risk of Spontaneous intracerebral hemorrhage: Systematic review and future directions.  407. 2019

Levodopa-carbidopa intestinal gel treatment of motor fluctuations and dyskinesia in advanced Parkinson’s disease patients in a ‘real world’ setting: Interim results from the DUOGLOBE study.  405:194-195. 2019

Epilepsy treatment patterns among patients with tuberous sclerosis complex.  391:104-108. 2018

Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.  388:203-207. 2018

Advancing stroke genomic research in the age of Trans-Omics big data science: Emerging priorities and opportunities.  382:18-28. 2017

Medical decision-making capacity and its cognitive predictors in progressive MS: Preliminary evidence.  380:38-43. 2017

Interleukin–6 (IL-6) rs1800796 and cyclin dependent kinase inhibitor (CDKN2A/CDKN2B) rs2383207 are associated with ischemic stroke in indigenous West African Men.  379:229-235. 2017

Caffeine, creatine, GRIN2A and Parkinson's disease progression.  375:355-359. 2017

Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population.  375:371-375. 2017

Olfactory ability in normal pressure hydrocephalus as compared to Alzheimer's disease and healthy controls.  372:217-219. 2017

Dissociation among hemodynamic measures in asymptomatic high grade carotid artery stenosis.  367:143-147. 2016

Evaluating the single seizure clinic model: Findings from a Canadian Center.  367:203-210. 2016

Neurogenomics in Africa: Perspectives, progress, possibilities and priorities.  366:213-223. 2016

Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial.  365:190-198. 2016

Gut microbiota composition and relapse risk in pediatric MS: A pilot study.  363:153-157. 2016

Relationship between symptom change, relapse activity and disability progression in multiple sclerosis.  362:121-126. 2016

Itemized NIHSS subsets predict positive MRI strokes in patients with mild deficits.  358:221-225. 2015

Neurocognitive interventions for breast cancer survivors: A state of the science.  357:e85. 2015

How long does it take to diagnose cervical dystonia?.  335:72-74. 2013

A long-term, open-label study of levodopa–/INS;carbidopa intestinal gel in advanced Parkinson's disease patients: Functional and health-related quality-of-life endpoints.  333:e123-e124. 2013

A long-term, open-label study of levodopa–/INS;carbidopa intestinal gel in advanced Parkinson's disease patients: safety and motor-symptom endpoints.  333:e127. 2013

Impaired cognitive function in patients with atherosclerotic carotid stenosis and correlation with ultrasound strain measurements.  322:20-24. 2012

Increasing age at disability milestones among MS patients in the MSBase Registry.  318:94-99. 2012

Implementing clinical trials on an international platform: Challenges and perspectives.  313:1-6. 2012

Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium.  307:22-29. 2011

Post-streptococcal vasculopathy with evolution to Degos' disease.  300:157-159. 2011

GABAergic but not anti-cholinergic agents re-induce clinical deficits after stroke.  292:72-76. 2010

FP39-WE-01 Long-term follow-up 20 years after the pivotal interferon beta-1b multiple sclerosis trial.  285:s118-s119. 2009

Pooled analysis of patients with thunderclap headache evaluated by CT and LP: Is angiography necessary in patients with negative evaluations?.  276:123-125. 2009

Intravenous thrombolysis followed by intra-arterial thrombolysis and mechanical thrombectomy for the treatment of pediatric ischemic stroke.  275:151-153. 2008

Chronic inflammatory demyelinating polyradiculoneuropathy presenting as cauda equina syndrome in a diabetic.  260:267-270. 2007

Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease.  229-230:285-292. 2005

CCR2-64I polymorphism and CCR5Δ32 deletion in patients with Alzheimer's disease.  225:79-83. 2004

Optimizing immunomodulatory therapy for MS patients: An integrated management model.  201:89-90. 2002

Differential cellular expression of tumor necrosis factor-α and Type I tumor necrosis factor receptor after transient global forebrain ischemia.  186:87-99. 2001

Elevated cerebrospinal fluid and serum nitrate and nitrite levels in patients with central nervous system complications of HIV-1 infection: A correlation with blood-brain-barrier dysfunction.  156:53-58. 1998

Raised serum nitrate and nitrite levels in patients with multiple sclerosis.  145:77-81. 1997

Aids-associated vacuolar myelopathy and tumor necrosis factor-alpha (TNFα).  138:134-144. 1996

Specificity of the clinical diagnosis of dementia.  26:81-98. 1975

The morphogenesis of hydranencephaly.  12:187-217. 1971